4D Molecular Therapeutics Inc (NASDAQ:FDMT) shares, rose in value on Friday, March 07, with the stock price down by -1.69% to the previous day’s close as strong demand from buyers drove the stock to $4.07.
Actively observing the price movement in the last trading, the stock closed the session at $4.14. Referring to stock’s 52-week performance, its high was $36.25, and the low was $3.92. On the whole, FDMT has fluctuated by -33.71% over the past month.
With the market capitalization of 4D Molecular Therapeutics Inc currently standing at about $188.45 million, investors are eagerly awaiting this quarter’s results, scheduled for in April.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 446.33k.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that FDMT’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of FDMT currently trading nearly -11.77% and -20.14% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 36.43, while the 7-day volatility ratio is showing 8.71% which for the 30-day chart, stands at 8.97%. Furthermore, 4D Molecular Therapeutics Inc (FDMT)’s beta value is 2.80, and its average true range (ATR) is 0.39.
A comparison of 4D Molecular Therapeutics Inc (FDMT) with its peers suggests the former has fared considerably weaker in the market. FDMT showed an intraday change of -1.69% in last session, and over the past year, it shrunk by -84.95%%.
Data on historical trading for 4D Molecular Therapeutics Inc (NASDAQ:FDMT) indicates that the trading volumes over the past 3 months, they’ve averaged 938.42K. According to company’s latest data on outstanding shares, there are 45.79 million shares outstanding.
Nearly 14.40% of 4D Molecular Therapeutics Inc’s shares belong to company insiders and institutional investors own 92.18% of the company’s shares. The stock has fallen by -26.93% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the FDMT stock heading into the next quarter.
